Get started
Author

Melinda Harbhajan

Observed name: M. Harbhajan
OpenAlex ID: A5115007345
MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses
2024 · Jia Ruan, David A. Bond, et al. · Blood · 7
PDF
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma
2025 · Jia Ruan, David A. Bond, et al. · Blood Advances · 6
PDF
The use and safety of peripheral intravenous catheters (PIV) vs central venous catheters (CVC) for lymphoma patients receiving frontline anthracycline-based chemotherapy: A large multicenter real-world analysis (RWA)
2025 · Yun Kyoung Tiger, Patrick Glennan, et al. · Blood
PDF
The use of peripheral intravenous catheters (PIV) for lymphoma patients receiving anthracycline-based chemotherapy: A multicenter real-world analysis (RWA).
2025 · Yun Kyoung Ryu Tiger, Patrick Glennan, et al. · JCO Oncology Practice
892 | the Use of Peripheral Intravenous Catheters for Lymphoma Patients Receiving Anthracycline‐based Chemotherapy: a Multicenter Real‐world Analysis
2025 · Y. K. Tiger, J. D. Lukowski, et al. · Hematological Oncology
PDF
The use of peripheral intravenous catheters (PIV) for lymphoma patients receiving anthracycline-based chemotherapy: A multicenter real-world analysis (RWA).
2025 · Yun Kyoung Ryu Tiger, Joe D. Lukowski, et al. · Journal of Clinical Oncology
PDF
Works count: 6
Citation count: 13
H-index: 2
I10-index:
Year
Topic
Type